Zhongtai Securities released a research report on April 23 stating that it gave Proplo Pharmaceutical (000739.SZ) a purchase rating. The main reasons for the rating include: 1) in line with expectations, steady growth in performance under industry pressure; 2) CDMO: maintaining rapid overall growth and increasing competitive strength; 3) API intermediates: veterinary drug prices are still in the bottom range, the antibiotic series has significant advantages, the market share of core products is rising steadily, focusing on DMF reporting, and steady growth; 4) cost ratio: gross profit ratio and cost ratio have remained stable, and R&D investment has been reduced appropriately. (Mainichi Keizai Shimbun)
中泰证券4月23日发布研报称，给予普洛药业（000739.SZ）买入评级。评级理由主要包括：1）符合预期，行业承压下业绩稳健增长；2）CDMO：整体保持快速增长，竞争实力不断增强；3）API中间体：兽药价格仍处底部区间，抗生素系列优势显著，核心产品的市场占有率稳中有升，注重DMF申报，增长稳健；4）费用率：毛利率、费用率保持稳定，研发投入适当收缩。（每日经济新闻）
Zhongtai Securities released a research report on April 23 stating that it gave Proplo Pharmaceutical (000739.SZ) a purchase rating. The main reasons for the rating include: 1) in line with expectations, steady growth in performance under industry pressur
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated